Internal medicine journal
-
Internal medicine journal · Oct 2015
Multicenter StudyIpilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Ipilimumab (Yervoy; Bristol-Myers Squibb) is a novel fully humanised monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4, an immune checkpoint molecule, to augment anti-tumour T-cell responses. It is associated with significant immune-related side-effects including hypophysitis. ⋯ There is significant morbidity associated with development of IH. We suggest guidelines to assist with early recognition and therapeutic intervention.